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This report is based on data (up to 31 March 2004) from the Renal Registry of the Hospital Authority of Hong
Kong, and accounts for 90–95% of all patients receiving renal replacement therapy (RRT) in the territory.
Patients receiving RRT in the private sector are not included in this report.
The number of patients receiving RRT was 6,054 (889 per million population [pmp]), of whom 51.6%
(3,123, 451 pmp) were receiving peritoneal dialysis (PD), 10.9% (662, 97 pmp) hemodialysis (HD), and
37.5% (2,269, 334 pmp) had functioning kidney transplants. The net increase from the previous year in the
number of patients receiving RRT was 3.1%. The incidence of end-stage renal failure in patients undergoing
RRT was 954 (140 pmp). The median ages of existing and new patients receiving RRT were 55 and 56 years,
respectively. There was a trend towards an increasing number of elderly dialysis patients. Diabetes was the
third major cause of renal failure among existing RRT patients and the most common cause of renal failure in
new cases. The rate of serologic positivity for hepatitis B infection in RRT patients was 9.68%, while that for
hepatitis C infection was 3.28%.
In Hong Kong, most patients were put on PD when RRT was required. Of all patients on dialysis, 83% were
on PD, of whom 94.8% were on continuous ambulatory peritoneal dialysis (CAPD). Most CAPD patients were
on disconnect systems. HD was used in 17.5% of all patients on dialysis. Of the 2,269 patients with functioning
kidney transplants, 836 (36.8%) were transplanted in Hong Kong. Of these, 495 (59.2%) had undergone cadaveric
kidney transplantation. Of all patients receiving RRT, 30% were receiving erythropoietin.
For the year ending 31 March 2004, the annual crude mortality rate for all RRT was 10% (15.3% for PD,
13% for HD, and 1.9% for transplantation). The major causes of death were infection, cardiovascular disease,
and cerebrovascular accident. The 1- and 5-year survival rates for patients with kidney transplantation performed
in Hong Kong between 1 April 1997 and 31 March 2003 were 98.6% and 96.5%, respectively, for living
related kidney transplants, and 96.1% and 91.2%, respectively, for cadaveric kidney transplants. The 1- and 5-
year graft survival rates were 91.1% and 86.1% (death censored) and 90.5% and 85.6% (death not censored)
for living related kidney transplants, and 89% and 83% (death censored) and 86% and 79% (death not censored)
for cadaveric kidney transplants. The overall peritonitis rate for all chronic PD systems for the year ending 31
March 2004 was one episode per 27.7 months. [Hong Kong J Nephrol 2005;7(1):38–46]
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INTRODUCTION
This report is based on data (up to 31 March 2004)
from the Renal Registry of the Hospital Authority (HA)
of Hong Kong, and accounts for 90–95% of all patients
receiving renal replacement therapy (RRT) in the
territory. There are 11 renal units, four satellite centers
and four major renal transplant centers in Hong Kong.
Patients receiving RRT in the private sector are not
included in this report.
HONG KONG RENAL REGISTRY/CLINICAL
INFORMATION SYSTEM
The Renal Registry, implemented by the HA of Hong
Kong on 1 April 1995, is a direct, online, computerized
registry. Computer terminals are installed in all the renal
units operated by the HA and are linked by a cable
network system to a central database at the HA head
office. Data are entered directly into the local computer
terminals and are stored in servers in the HA head office.
There is no need to manually complete annual report
forms. As a computerized clinical information system,
individual renal units can use the Renal Registry as a
database for clinical management. The data entered can
be directly analyzed online. The Renal Registry also
allows the HA head office to compile a registry report
for the whole territory of Hong Kong.
The Renal Registry is linked with other related
computerized systems. It allows automatic download
of the following information: a donor’s data from the
“Organ Procurement System” used by transplant
coordinators; and individual human leukocyte antigen
data from the “Tissue Typing Laboratory System”.
The registry is the platform for fair cadaveric kidney
allocation by providing computer-generated scores for
potential recipients.
PREVALENCE AND INCIDENCE
The number of patients receiving RRT on 31 March
2004 was 6,054, with a prevalence of 889 per million
population (pmp), and an incidence of 140 pmp. In the
12 months ending 31 March 2004, 954 new patients
started RRT; this was an increase of 188 patients from
the previous 12-month period. Among the patients
receiving RRT, 3,123 (51.6%) were receiving peritoneal
dialysis (PD), 662 (10.9%) hemodialysis (HD), and
2,269 (37.5%) were living with a functioning graft.
Among dialysis patients, 82.5% were undergoing PD,
and 17.5% HD.
From 1996–2004, an increasing trend in the
prevalence of RRT was noted, although the rate of
increase was reduced (Figure 1). The net reduction in
the increase appeared more dramatic in the year 2003–
2004, when Hong Kong was affected by severe acute
respiratory syndrome (SARS) and the incidence of RRT
actually dropped, not because of a change in the
population, but possibly because patients avoided
hospitals and seeking active treatment during the SARS
period. Changes were noted in the proportion of patients
undergoing the various forms of RRT: the rate of
increase in PD slowed gradually, whereas the number
of patients with functioning renal allografts increased
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steadily (Figure 1). Clearly, the proportion of patients
on transplant treatment increased. However, the total
number of patients also increased, although this increase
was slowed by SARS in the year ending 31 March 2004.
The incidence of RRT (Figure 2) appeared to reach a
plateau at around 1,000–1,020 cases (147–150 pmp) per
year, although the figure for the year ending 31 March
2004 was probably affected by the SARS epidemic.
DEMOGRAPHIC DATA
Age
For the year ending 31 March 2004, the median age of
patients receiving RRT was 55 years: 35.6% of patients
were aged > 60 years, 20.9% were in their sixties, and
14.7% were aged > 70 years (Figure 3). For new RRT
patients, the median age was 56 years: 40.1% of new
patients were aged > 60 years, 20.9% were in their
sixties, and 19.2% were aged > 70 years (Figure 4).
Thus, an increasing number of elderly patients were
receiving RRT.
From 1996–2004, there was an increase in the
median age of existing RRT recipients from 49 to 55
years (Figure 5). There was also a trend towards an
increasing proportion of RRT recipients aged > 60 years
(Figure 6). A similar trend was observed in new RRT
recipients, with median age increasing from 54 to 56
years. For the year ending 31 March 2004, the
proportion of elderly, new RRT recipients had declined,
but again, this may have been related to the SARS
epidemic (Figure 7).
Figure 1. Trends in the prevalence of renal replacement therapy
(as of 31 March each year). PD = peritoneal dialysis; HD =
hemodialysis; Tx = transplantation.
Figure 2. Incidence of renal replacement therapy (as of 31 March
each year).
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Figure 4. Percentage age distribution for new renal replacement
therapy recipients (for year ending 31 March 2004).
Figure 3. Percentage age distribution for existing renal replacement
therapy recipients (as of 31 March 2004).
Figure 5. Median age of existing renal replacement therapy
recipients (as of 31 March each year).
Figure 6. Trends in the age of existing renal replacement therapy
recipients (as of 31 March each year).
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Gender
The male:female (M:F) ratios of patients with func-
tioning renal allografts or on HD or PD from 1996
to 2004 are shown in Figure 8. There were variations
in the gender distribution of patients according to the
three different types of RRT. The overall M:F ratio (as
of 31 March 2004) for patients on RRT was 1:1.12,
that for patients who had undergone renal trans-
plantation was 1.44:1, that for patients on HD was
1.07:1, and that for patients on PD was 0.95:1.
Among transplant recipients during the last 5–6
years, the M:F ratio was relatively constant. More male
than female patients had functioning renal allografts.
More than 60% of patients underwent renal trans-
plantation outside the Hong Kong Special Adminis-
trative Region (SAR); thus, the male preponder-
ance was probably the result of more men than
women going to China for renal transplantation.
There was a trend towards more male than female
patients undergoing HD in the last 5–6 years; however,
the ratio decreased over this period and approached
unity in the year ending 31 March 2004.
There were fewer male than female patients
maintained on PD. To some extent, this may have been
because more male than female patients underwent
renal transplantation.
Primary renal disease
For existing patients receiving RRT, glomerulonephritis
(GN) was the most common cause of renal failure
(34.8% of patients), whereas “unknown” causes and
diabetes mellitus were ranked second and third,
respectively (Figure 9).
The prevalence of diabetic nephropathy increased
from 13% in 1996 to 22% in 2004. The number of new
patients presenting with diabetic nephropathy increased
from 25.3% in 1996 to 38.0% in 2004 (Figure 10). Thus,
the trend was increasing, although the rate of increase
appeared to slow down.
Regarding the different types of GN leading to end-
stage renal disease (ESRD) in existing RRT recipients
on 31 March 2004, 53.4% of GN cases were primary
GN, 9.8% were secondary GN (excluding diabetic
nephropathy), 5.2% were advanced sclerosing GN,
and 31.6% were suspected GN not proven by biop-
sy. Biopsy-proven primary GN was identified as
immunoglobulin-A nephropathy (60.8% of cases), focal
segmental glomerulosclerosis (12.7%), mesangial-
capillary GN (5.3%), membranous GN (5.1%),
Figure 7. Trends in the age of new renal replacement therapy
recipients (as of 31 March each year).
Figure 8. Male:female ratio among patients receiving different
types of renal replacement therapy (RRT) (as of 31 March each
year). Tx = transplantation; HD = hemodialysis; PD = peritoneal
dialysis.
Figure 9. Primary renal disease leading to end-stage renal disease
in patients receiving any form of renal replacement therapy (as of
31 March 2004). GN = glomerulonephritis; cong = congenital;
HT = hypertension; DM = diabetes mellitus.
Figure 10. Diabetic nephropathy leading to end-stage renal disease
in patients receiving any form of renal replacement therapy (as of
31 March each year).
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crescentic GN (4.8%), and other miscellaneous GNs
(11.3%). The main cause of secondary GN was systemic
lupus erythematosus (79.7% of cases).
Comorbid risk factors
Hepatitis B and C infection
As of 31 March 2004, 9.8% of all patients receiving
RRT were serologically positive for hepatitis B virus
(HBV) infection (PD, 9.6%; HD, 9.4%; transplantation,
9.9%). The prevalence of HBV carrier status among
RRT recipients remained steady during the past 5 years,
although the prevalence among PD patients appeared
to decrease (Figure 11).
Among all RRT recipients, 3.28% had hepatitis C
virus (HCV) infection (PD, 1.8%; HD, 7.6%; trans-
plantation, 4.2%). Trends for HCV infection during the
past 10 years are shown in Figure 12. The prevalence
of HCV infection decreased among HD and transplant
patients, but remained static in PD patients, during the
past 4 years.
Diabetes mellitus
When diabetes mellitus was counted as comorbidity,
on 31 March 2004, 27.5% of all RRT recipients were
diabetics (PD, 38.5%; HD, 22.7%; transplantation,
12.2%). The growing trend towards an increased
number of RRT recipients with diabetes is shown in
Figure 13. The increasing prevalence of diabetes in the
general population is also reflected in patients receiving
RRT, and such prevalence in the general population
continues to increase.
RENAL REPLACEMENT THERAPY
Peritoneal dialysis (PD)
All new patients requiring RRT were started on PD
unless contraindicated or unless pre-emptive renal
transplantation had been arranged. Most renal
transplantations were performed outside the Hong
Kong SAR. The funding for dialysis fluid was mainly
supported by the HA.
Among RRT recipients, 62.5% were undergoing
dialysis therapy. Among the latter patients, 82.5% were
on PD (i.e. 51.6% of patients requiring RRT were
on PD). As of 31 March 2004, 3,069 patients were
maintained on PD (459 pmp), and among these, 2,909
(94.8%) were receiving continuous ambulatory
peritoneal dialysis (CAPD), and 135 (4.4%) were re-
ceiving automated PD (APD), i.e. night intermittent
peritoneal dialysis or continuous cyclic peritoneal
dialysis. The remaining patients were on intermittent
PD in hospital or at home. The net increase from the
previous year in the number of patients maintained on
PD was 43 (+1.4%). This was exceptionally low when
compared with figures from previous years (Figure 14),
Figure 11. Prevalence of hepatitis B virus infection among renal
replacement therapy (RRT) recipients (as of 31 March each year).
PD = peritoneal dialysis; HD = hemodialysis; Tx = transplantation.
Figure 12. Prevalence of hepatitis C virus infection among renal
replacement therapy (RRT) recipients (as of 31 March each year).
PD = peritoneal dialysis; HD = hemodialysis; Tx = transplantation.
Figure 13. Prevalence of diabetes mellitus among renal replace-
ment therapy recipients (as of 31 March each year).
Figure 14. Net increase in peritoneal dialysis patients (years
ending 31 March, 1996–2004).
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and the percentage change is shown in Figure 15. The
reduced net growth in PD in the last year (2003–2004)
is partly the result of the SARS epidemic and partly
related to an increase in pre-emptive transplantation in
patients requiring RRT.
There was an increasing trend in the number of
patients receiving APD. However, the rate of increase
became less in the last 3 years of the analysis period
(2001–2004; Figure 16).
Figure 17 shows the trend for CAPD use from 1996
to 2004. There was an increasing trend in the number
of CAPD patients, although the rate of increase was
reduced in the year ending 31 March 2004.
As of 31 March 2004, most CAPD patients (94.5%)
were using disconnecting systems; only 0.83% of
patients were using connect systems, and 3.95% re-
quired the use of a device (UV FlashTM system; Baxter
Healthcare Ltd, Hong Kong SAR, China) for CAPD
exchanges. Trends in the use of connecting and dis-
connecting systems are shown in Figure 18.
Among patients using disconnect systems, 68.5%
were using a Baxter Ultrabag® (Baxter Healthcare Ltd),
27.9% were using a Fresenius StaySafe or A.N.D.Y.
Disc System (Fresenius Medical Care Asia-Pacific Ltd,
Hong Kong SAR, China), 2.8% were using Gambrosol
Trio (Gambro China Ltd, Hong Kong SAR, China),
and 0.9% were using other systems. Figure 19 shows
trends in the use of various connecting systems from
1995–2004.
Hemodialysis (HD)
Most patients commencing HD were switched from
other forms of RRT, in particular after failure of PD
therapy. Patients receiving regular hemodiafiltration
were counted as being on HD in the report. Hospital-
based and satellite center-based HD was funded by the
Hong Kong government via the HA. Patients were re-
quired to pay a small hospital attendance fee. Patients
receiving HD at charitable centers paid for their own
HD at a subsidized rate. The number of patients re-
ceiving HD at private centers was underestimated
by the report.
As of 31 March 2004, 662 patients (97 pmp) were
on HD, comprising 11.2% of all RRT patients and
17.5% of all dialysis patients. Among these HD pa-
tients, 416 (62.8%) were receiving hospital-based
HD, 96 (14.5%) satellite center-based HD, 74 (11.2%)
charitable center-based HD, and three (0.4%) home HD.
There was no net increase from the previous year in
the number of patients on HD (Figure 20).
Kidney transplantation
As of 31 March 2004, there were 2,269 patients (334
pmp) with a functioning kidney graft, constituting
37.5% of RRT recipients. Among these 2,269, 836
(36.8%) underwent transplantation in Hong Kong; other
renal transplants were performed overseas. Of the
transplants performed in Hong Kong, 495 (59.2%) were
cadaveric and 341 (40.8%) were from living related
Figure 15. Percentage net growth in peritoneal dialysis patients
(years ending 31 March, 1996–2004).
Figure 16. Number of automated peritoneal dialysis (APD) patients
(years ending 31 March, 1996–2004).
Figure 17. Number of continuous ambulatory peritoneal dialysis
patients (as of 31 March each year).
Figure 18. Percentage trends in the use of connecting and dis-
connecting systems (as of 31 March each year).
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donors. The growing trends in the number of patients
undergoing transplantation and in the number of
transplants performed at HA hospitals and overseas are
shown in Figure 21.
In the year ending 31 March 2004, 247 patients
(36.3 pmp) underwent kidney transplantation: 48
transplants were performed in Hong Kong (40 with
cadaveric kidneys and eight with living related donor
kidneys); and 199 patients underwent transplantation
overseas.
Erythropoietin
For the year ending 31 March 2004, 29.5% of all RRT
patients (1,123 patients; 165 pmp) received erythro-
poietin therapy, thus representing an increase of 1%
from the previous year. Considerably fewer PD than
HD patients were receiving erythropoietin (22.3% vs
61.6%). The growing trend in the number of patients
treated with erythropoietin is shown in Figure 22.
OUTCOMES
Crude mortality rates and causes of death
The mortality rate was defined as the rate of death
among all patients treated during the period of the
report. The annual crude mortality rate for the year
ending 31 March 2004 for all types of RRT was 10%
(15.3% for PD, 13.1% for HD, and 1.9% for trans-
plantation). Trends in the crude mortality rate are
shown in Figure 23.
The main causes of death were infection (30.4%
of patients) and cardiovascular disease (28.1%).
Percentage trends for the various causes of death in
PD, HD and renal transplant patients are shown in
Figures 24, 25 and 26, respectively.
Patient survival rates
PD and HD patients
From April 1995 to March 2003, the overall 1-year
patient-survival rate for all modes of PD treatment was
95.7%, and the 5-year survival rate was 49.8%. Figure
27 shows the life table plot of overall patient survival
Figure 19. Percentage distribution of connecting and disconnecting
systems (1995–2004).
Figure 20. Number of patients on hemodialysis at various locations
(as of 31 March each year).
Figure 21. Number of patients with functioning renal allografts:
transplantation performed at Hospital Authority (HA) hospitals and
overseas. cad = cadaveric; LR = living related donor.
Figure 22. Number of patients receiving erythropoietin (as of 31
March each year).
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for patients on PD.
During the same period, the overall 1-year patient-
survival rate for all modes of HD treatment was
85.6%, and the 5-year survival rate was 55.3%. The
majority of patients commenced HD after PD technique
failure. This may account for the relatively low 5-year
survival rate.
Renal transplant patients
For living related kidney transplants performed in
Hong Kong between 1 April 1997 and 31 March 2003,
1- and 5-year patient survival rates were 98.6% and
96.5%, respectively. Graft survival rates at 1 and 5 years
were 91.1% and 86.1% (death censored), and 90.5%
and 85.6% (death not censored).
For cadaveric kidney transplants performed in
Hong Kong between 1 April 1997 and 31 March 2003,
1- and 5-year patient survival rates were 96.1% and
91.2%, respectively. Graft survival rates at 1 and 5 years
were 92.5% and 84.4% (death censored), and 91.0%
and 81.7% (death not censored).
The 5-year patient survival rates for HBV-positive
and HCV-positive patients were 88.2% and 89.4%,
respectively; these rates were lower than the overall
survival rates for renal transplant patients.
Peritonitis rates
The overall rate of peritonitis associated with all chronic
PD systems, for the year ending 31 March 2004, was
Figure 23. Trends in annual crude mortality (years ending 31
March, 1996–2004). RRT = renal replacement therapy; PD =
peritoneal dialysis; HD = hemodialysis; Tx = transplantation.
Figure 24. Percentage trends in causes of death in peritoneal
dialysis patients (years ending 31 March, 1996–2004). CVA =
cerebrovascular accident; CV = cardiovascular disease.
Figure 25. Percentage trends in causes of death in hemodialysis
patients (years ending 31 March, 1996–2004). CVA = cerebro-
vascular accident; CV = cardiovascular disease.
Figure 26. Percentage trends in causes of death in renal transplant
recipients (years ending 31 March, 1996–2004). CVA = cerebro-
vascular accident; CV = cardiovascular disease.
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one episode per 27.7 months. The rates of peritonitis
varied with different systems (Figure 28): Baxter spike
system, 1 in 41.3 patient-months; Baxter Ultrabag®,
1 in 32.3 patient-months; Baxter UV FlashTM, 1 in 17.8
patient-months; Fresenius StaySafe device and A.N.D.Y.
Disc, 1 in 23.4 patient-months; Gambrosol Trio, 1
in 14.2 patient-months; and APD, 1 in 37.6 patient-
months. The rate of peritonitis with the Baxter spike
system was exceptionally good in the year ending 31
March 2004. This might explain why some patients
surviving with the Spike System are reluctant to change to
the disconnect systems that are commonly used nowadays.
DISCUSSION
Most of the ESRD patients in Hong Kong commenced
RRT with PD; indeed, most patients received CAPD.
Over the period of analysis (1996–2004), the number
of patients receiving PD increased, although the rate
of growth declined in the most recent years. The
introduction of more physiologic solutions and the use
of non-glucose-based solutions are important for
maintaining health in CAPD patients. Expansion of the
capacity for managing HD patients is also required in
Hong Kong to cope with the increasing demands of
dialysis support for HD programs. Growth in the
transplant population was also significant in the past 5
years, and the efficient use of resources and introduction
of new immunosuppressive agents are essential in the
maintenance of this increasing pool of transplant
patients. The increasing number of new diabetic patients
reflects the increasing prevalence of diabetes in the
Figure 27. Life table plot of overall survival in peritoneal dialysis
patients.
general population. Thus, improved management of
diabetic patients, and prevention of renal failure in the
first place, should be major clinical goals.
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Figure 28. Peritonitis rates (patient-months/episode) for different
connecting systems (for the year ending 31 March 2004). NIPD =
night intermittent peritoneal dialysis; CCPD = continuous cyclic
peritoneal dialysis; APD = automated peritoneal dialysis.
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